Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Hasbani Launched the National Campaign for the Prevention of Cardiovascular Diseases: No.1 Cause of Hasbani Launched the National Campaign for the Prevention of Cardiovascular Diseases: No.1 Cause of Death in Lebanon

 
The Ministry of Public Health launched in collaboration with the national committee for the prevention of cardiovascular diseases and Yaduna -Women Heart Health Center the National campaign for the early detection and prevention of cardiovascular diseases under the title “Don’t wait, your heart can’t wait”, during a conference held under the patronage and in the presence of Deputy Prime Minister Health Minister Ghassan Hasbani at the Adnan Kassar Edifice in Bir Hassan.
 
The Head of Primary health care Department at Health Ministry Dr. Randa Hamadeh made a presentation of the path of the national campaign. “This campaign that starts today will last for three months until the end of April. It will kick off from the national network of primary health care centers located across all the Lebanese territory and aims at providing services to citizens, i.e. free cardiovascular examinations for men and women,”Dr. Hamadeh added.
 
The Chairperson of Yaduna foundation Wafaa Sleiman delivered a statement in which she noted that the increasing number of women who underwent an early testing at the Women Heart Health Center, and the detection of many cases of cardiovascular diseases contributed greatly in the treatment of these cases, and led us to activate the prevention and awareness actions across all the Lebanese territory.
 
Hasbani

In a statement, Hasbani noted that the non-communicable diseases cause the death of 38 million people each year, 28 million death cases of which occur in low- and middle-income countries.

“Non-communicable diseases threaten the progress towards achieving the Millennium Development Goals. Poverty and such diseases are highly correlated and it is expected that the rapid growth of these diseases hinder poverty alleviation initiatives in low-income countries, in particular by increasing household costs associated with healthcare services,” Hasbani added.
 
Hasbani highlighted that this activity complements all these efforts, especially that it is integrated with that of Yaduna - Women Heart Health Center, knowing that the primary healthcare brings together all sectors to provide best services to citizens.(Read more...)
    1
    ...
ATC Name B/G Ingredients Dosage Form Price
B05BB01 R-SOL G Calcium chloride, 2H2O - 0.033%, Potassium chloride - 0.03%, Sodium chloride - 0.86% Injectable solution 205,933 L.L
A02BC04 RABEC G Rabeprazole (sodium) - 10mg 10mg Tablet, film coated 212,327 L.L
A02BC04 RABEC G Rabeprazole (sodium) - 20mg 20mg Tablet, film coated 212,327 L.L
A02BC04 RABEZOL 20 G Rabeprazole sodium - 20mg 20mg Tablet, enteric coated 282,847 L.L
A02BC04 RABEZOL 20 G Rabeprazole sodium - 20mg 20mg Tablet, enteric coated 639,925 L.L
J06BB05 RABISHIELD-100 (RABIES HUMAN MONOCLONAL ANTIBODY rDNA) BioHuman Rabies, Human IgG1 Monoclonal Antibody - 100IU/2.5ml 100IU/2.5ml 8,455,824 L.L
J07BG01 RABIVAX-S (RABIES VACCINE INACTIVATED) BioTech Freeze dried inactivated purified rabies antigen (Pitman Moore PM3218 as virus strain) - Injectable freeze dried material 1,552,138 L.L
A07XA04 RACECADOTRIL ARROW G Racecadotril - 100mg 100mg Capsule 583,228 L.L
A07XA04 RACECADOTRIL BGR G Racecadotril - 100mg 100mg Capsule 575,165 L.L
A07XA04 RACECADOTRIL BIOGARAN CONSEIL G Racecadotril - 100mg 100mg Capsule 287,582 L.L
H02AB02 RADOLINE G Dexamethasone sodium phosphate - 8mg/2ml 8mg/2ml Injectable solution 3,711,565 L.L
G03XC01 RALOXIFENE ARROW G Raloxifene HCl - 60mg 60mg Tablet, coated 1,425,817 L.L
P01AB01 RAMAZOL G Metronidazole - 500mg 500mg Tablet 216,359 L.L
A02BC04 RAMEP G Rabeprazole (sodium) - 20mg 20mg Tablet, gastroresistant 518,809 L.L
C09AA05 RAMIPRIL-REMEDICA G Ramipril - 5mg 5mg Tablet 623,543 L.L
C09AA05 RAMIPRIL-REMEDICA G Ramipril - 10mg 10mg Tablet 896,343 L.L
C09BB07 RAMIPRIL/AMLODIPINE GENERICON G Ramipril - 2.5mg, Amlodipine - 5mg Capsule, hard 1,358,625 L.L
C09BB07 RAMIPRIL/AMLODIPINE GENERICON G Ramipril - 5mg, Amlodipine - 5mg Capsule, hard 1,358,625 L.L
C09BB07 RAMIPRIL/AMLODIPINE GENERICON G Ramipril - 10mg, Amlodipine - 5mg Capsule, hard 1,358,625 L.L
C09BB07 RAMIPRIL/AMLODIPINE GENERICON G Ramipril - 10mg, Amlodipine - 10mg Capsule, hard 1,358,625 L.L
C01EB18 RANEXA B Ranolazine - 375mg 375mg Tablet, prolonged release 3,985,837 L.L
C01EB18 RANEXA B Ranolazine - 500mg 500mg Tablet, prolonged release 3,985,837 L.L
C01EB18 RANEXA B Ranolazine - 750mg 750mg Tablet, prolonged release 3,985,837 L.L
L04AA10 RAPAMUNE B Sirolimus - 1mg 1mg Tablet 12,907,489 L.L
L04AA10 RAPAMUNE B Sirolimus - 1mg 1mg Tablet L.L
R05DB13 RAPICOD G Butamirate citrate - 0.15% 0.15% Syrup 296,989 L.L
M01AB05 RAPIDUS G Diclofenac potassium - 50mg 50mg Tablet, coated 287,582 L.L
N04BD02 RASAGILINE BIOGARAN G Rasagiline - 1mg 1mg Tablet 5,214,109 L.L
G04BE08 RAVANA G Tadalafil - 20mg 20mg Tablet 500,421 L.L
G04BE08 RAVANA G Tadalafil - 5mg 5mg Tablet 1,501,264 L.L
    1
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026